Docetaxel-loaded biomimetic nanoparticles for targeted lung cancer therapy in vivo

Chi, Changliang; Li, Fuwei; Liu, Huibo; Feng, Shiyun; Zhang, Yanjun; Zhou, Da; Zhang, Rongkui

doi:10.1007/s11051-019-4580-8

Cited by 41 publications

(21 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Emerging preclinical and clinical studies combining DTX with novel interventions, like nanomedicines and therapeutic nanotechnologies, offer a renewed potential for DTX dose reduction and enhanced drug delivery [17,[25][26][27][28][29][30][31]42,43]. A variety of nanomaterials have impacted DTX effectiveness by allowing for selective distribution to the cancer cells, increased circulation times, and a more sustained drug release [26][27][28].…”

Section: Discussionmentioning

confidence: 99%

“…A variety of nanomaterials have impacted DTX effectiveness by allowing for selective distribution to the cancer cells, increased circulation times, and a more sustained drug release [26][27][28]. Furthermore, surface-coated nanoparticles may significantly increase targeting, decrease immunogenicity, and suppress nonspecific binding to charged molecules [29][30][31]. Similar to our approach, Bannister et al used PEGylated gold nanoparticles (GNPs) in tandem with DTX and radiotherapy as a therapeutic strategy, rather than a drug delivery system [17].…”

Section: Discussionmentioning

confidence: 99%

“…These nanomedicines have demonstrated dramatic improvement in tumor targeting and therapeutic efficacy when used in drug delivery systems, radiotherapy, and photothermal or photodynamic therapy [18][19][20][21][22][23][24]. Many nano-based approaches have been combined with DTX to enhance targeted drug delivery and tumor specificity, consequently minimizing side effects [17,[25][26][27][28][29][30][31]. Photothermal therapies utilizing nanoparticles and laser light have shown success in tumor treatment in vitro and in vivo as a site-specific ablative approach rather than theranostic drug delivery [32,33].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Assessment of a Nano-Docetaxel Combined Treatment for Head and Neck Cancer

Lee¹,

Mubasher²,

McKenzie³

et al. 2021

Preprint

View full text Add to dashboard Cite

Objective: The combination of docetaxel (DTX) with Laser-Activated NanoTherapy (LANT), as a treatment for head and neck cancer (HNC) may enhance the therapeutic efficacy of lower doses of DTX, thereby minimizing the effective dosage, side effects and treatment times. Material and methods: Three HNSCC cell lines, Detroit 562, FaDu, and CAL 27, were treated with four combinations of DTX + LANT to evaluate DTX dose reduction and cell viability. Results: The 1 nM DTX + 5 nM LANT combination was the most effective treatment, increasing cell death over its corresponding DTX monotreatment with approximately 86.6%, 80.7%, and 92.1% cell death for Detroit 562, FaDu, and CAL 27, respectively. In Detroit 562, the 1 nM DTX + 5 nM LANT combination treatment resulted in the highest percentage of DTX dose reduction at 84.6%; in FaDu and CAL 27, the 0.5 nM DTX + 5 nM LANT combination treatment resulted in the highest percentage of DTX dose reduction at 78.2% and 82.4%, respectively. Conclusion: LANT may increase the therapeutic efficacy of DTX at significantly lower doses, which could improve patient outcomes.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Assessment of a Nano-Docetaxel Combined Treatment for Head and Neck Cancer

Lee¹,

Mubasher²,

McKenzie³

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…Another effective way to actively target lung cancer cells was shown by Chi et al, in which they developed a DCX-loaded PLGA NP conjugated with platelet membrane (PM) [ 109 ]. PM was chosen as targeting agent as it can prolong the circulation time of the carrier, it also possesses multiple adhesions molecules (i.e., glycoprotein Ib-IX-V, glycoprotein VI, C-type lectin-like-2-receptor, P-selectin and six different integrins) to selectively bind to tumor cells [ 110 ], and immune escape capabilities by decreasing the RES clearance [ 111 ].…”

Section: Drug Delivery For DCXmentioning

confidence: 99%

Advances in Nanocarriers for Effective Delivery of Docetaxel in the Treatment of Lung Cancer: An Overview

Razak

Gazzali

Fisol

et al. 2021

Cancers

View full text Add to dashboard Cite

Docetaxel (DCX) is a highly effective chemotherapeutic drug used in the treatment of different types of cancer, including non-small cell lung cancer (NSCLC). The drug is known to have low oral bioavailability due to its low aqueous solubility, poor membrane permeability and susceptibility to hepatic first-pass metabolism. To mitigate these problems, DCX is administered via the intravenous route. Currently, DCX is commercially available as a single vial that contains polysorbate 80 and ethanol to solubilize the poorly soluble drug. However, this formulation causes short- and long-term side effects, including hypersensitivity, febrile neutropenia, fatigue, fluid retention, and peripheral neuropathy. DCX is also a substrate to the drug efflux pump P-glycoprotein (P-gp) that would reduce its concentration within the vicinity of the cells and lead to the development of drug resistance. Hence, the incorporation of DCX into various nanocarrier systems has garnered a significant amount of attention in recent years to overcome these drawbacks. The surfaces of these drug-delivery systems indeed can be functionalized by modification with different ligands for smart targeting towards cancerous cells. This article provides an overview of the latest nanotechnological approaches and the delivery systems that were developed for passive and active delivery of DCX via different routes of administration for the treatment of lung cancer.

show abstract

“…Collectively, these aforementioned studies suggested that ACBP may be a potential tumor stem cell-targeted drug and when combined with chemotherapeutic drugs, ACBP may effectively improve their therapeutic efficacy and reduce their toxicity in patients (22). Docetaxel (DTX) is an effective anticancer agent that is widely used and has demonstrated extensive anticancer activity against breast, lung, pancreatic, prostate, ovarian and head and neck cancer (23)(24)(25)(26). DTX is one of the most commonly used chemotherapy drugs for breast cancer (23).…”

Section: Introductionmentioning

confidence: 99%

Anticancer bioactive peptide combined with docetaxel and its mechanism in the treatment of breast cancer

Gao

2020

Exp Ther Med

View full text Add to dashboard Cite

Breast cancer remains a worldwide public-health issue. Novel drugs that increase the sensitivity and reduce the toxic side effects of chemotherapeutic agents are urgently required. The present study investigated the effect and mechanism of the short-term intermittent administration of an anticancer bioactive peptide (ACBP), docetaxel (DTX), ACBP combined with DTX (MIX) and ACBP combined with low dose DTX (L-MIX) to nude mice bearing human breast cancer tumors. The body weight, tumor length, tumor diameter, diet and water consumption of the tumor-bearing nude mice were calculated. The protein and mRNA expression levels of p53, p21 and Ki67 were detected via immunohistochemistry and reverse transcription-quantitative PCR, respectively. The results revealed that the activity level of each group of mice was consistent. However, the food and water consumption of the ACBP group was significantly increased compared with the NS group. Compared with the normal saline group, the tumor weights and volumes of the treatment groups were significantly decreased, indicating an inhibitory effect of the treatment. However, the MIX group exhibited lower tumor weights and volumes compared with the ACBP and DTX groups. Furthermore, no significant cell necrosis, edema or inflammatory cell infiltration was observed upon hematoxylin & eosin staining of the liver and spleen in all groups. The results also revealed that the p21, p53 and Ki67 protein and mRNA levels were decreased in the ACBP, DTX and MIX groups compared with the control group. Additionally, when compared with those in the MIX and L-MIX groups, the p21 and Ki67 protein, and p53 and Ki67 mRNA levels in the ACBP and DTX groups were significantly increased. The results suggested that the short-term intermittent use of ACBP alone had an inhibitory effect on tumor growth and improved the food and water consumption of tumor-bearing nude mice. Furthermore, the combination of ACBP and DTX reduced toxic side effects and the dosage requirement of drugs to achieve therapeutic effects on the tumor-bearing nude mice. Therefore, the antitumor effect of ACBP may be associated with the improvement of immune function in tumor-bearing nude mice and ACBP may serve an antitumor role via the p53-p21 signaling pathway in breast cancer.

show abstract

Docetaxel-loaded biomimetic nanoparticles for targeted lung cancer therapy in vivo

Cited by 41 publications

References 24 publications

Assessment of a Nano-Docetaxel Combined Treatment for Head and Neck Cancer

Assessment of a Nano-Docetaxel Combined Treatment for Head and Neck Cancer

Advances in Nanocarriers for Effective Delivery of Docetaxel in the Treatment of Lung Cancer: An Overview

Anticancer bioactive peptide combined with docetaxel and its mechanism in the treatment of breast cancer

Contact Info

Product

Resources

About